SE9101815L - Behandling av sjukdom foerbunden med hiv-infektioner - Google Patents

Behandling av sjukdom foerbunden med hiv-infektioner

Info

Publication number
SE9101815L
SE9101815L SE9101815A SE9101815A SE9101815L SE 9101815 L SE9101815 L SE 9101815L SE 9101815 A SE9101815 A SE 9101815A SE 9101815 A SE9101815 A SE 9101815A SE 9101815 L SE9101815 L SE 9101815L
Authority
SE
Sweden
Prior art keywords
treatment
diseases associated
hiv infections
cysteine
transported
Prior art date
Application number
SE9101815A
Other languages
English (en)
Swedish (sv)
Other versions
SE9101815D0 (sv
Inventor
W Droge
Original Assignee
Leonore A Herzenberg
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leonore A Herzenberg, Zambon Spa filed Critical Leonore A Herzenberg
Publication of SE9101815L publication Critical patent/SE9101815L/xx
Publication of SE9101815D0 publication Critical patent/SE9101815D0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
SE9101815A 1989-01-26 1991-06-13 Behandling av sjukdom foerbunden med hiv-infektioner SE9101815D0 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30239689A 1989-01-26 1989-01-26
PCT/US1990/000363 WO1990008540A1 (en) 1989-01-26 1990-01-24 Treatment of disease associated with hiv-infections

Publications (2)

Publication Number Publication Date
SE9101815L true SE9101815L (sv) 1991-06-13
SE9101815D0 SE9101815D0 (sv) 1991-06-13

Family

ID=23167578

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9101815A SE9101815D0 (sv) 1989-01-26 1991-06-13 Behandling av sjukdom foerbunden med hiv-infektioner

Country Status (25)

Country Link
US (1) US5607974A (ja)
JP (1) JPH04504570A (ja)
KR (1) KR940002820B1 (ja)
AU (1) AU639686B2 (ja)
BE (1) BE1004168A3 (ja)
CA (3) CA1339070C (ja)
CH (1) CH683499A5 (ja)
DE (1) DE4090165T (ja)
DK (1) DK139191A (ja)
FR (1) FR2643557B1 (ja)
GB (1) GB2243296B (ja)
GR (1) GR900100048A (ja)
IE (1) IE62795B1 (ja)
IL (1) IL93162A (ja)
IT (1) IT1237999B (ja)
LU (1) LU87977A1 (ja)
MA (1) MA21739A1 (ja)
MX (1) MX173567B (ja)
NL (1) NL9020094A (ja)
OA (1) OA09503A (ja)
PT (1) PT92949B (ja)
SE (1) SE9101815D0 (ja)
TN (1) TNSN90009A1 (ja)
WO (1) WO1990008540A1 (ja)
ZA (1) ZA90245B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205549A (es) * 1991-09-30 1993-05-01 Jess G Thoene Metodo para el tratamiento de vih.
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
EP0600462A1 (en) * 1992-12-01 1994-06-08 Nippon Flour Mills Co., Ltd. Reverse transcriptase inhibitors and antiviral agents
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
DE4325547C2 (de) * 1993-07-29 1997-11-27 Max Planck Gesellschaft Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
EP0789565A4 (en) * 1993-10-15 1999-03-24 Jess G Thoene PREVENTION OF HIV INFECTION
US5725870A (en) * 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
US5786152A (en) * 1996-04-26 1998-07-28 Amgen Inc. Methods of inhibiting syp binding to a CTLA-4 receptor
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
TW517089B (en) 1996-09-03 2003-01-11 Res Dev Foundation Assessment of intracellular cysteine and glutathione concentrations
JP4578578B2 (ja) * 1997-01-13 2010-11-10 エモリー、ユニバーシティ インフルエンザ感染の治療用化合物及びそれらの組み合わせ
US6331610B1 (en) * 1997-04-25 2001-12-18 Metatron, Inc. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
US6020205A (en) * 1998-04-10 2000-02-01 Immunosciences Lab, Inc. Determination of intracellular antioxidant levels
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
US20050070607A1 (en) * 2003-08-19 2005-03-31 James Andrus N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
JP5027512B2 (ja) 2003-11-14 2012-09-19 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫調節法
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20070053970A1 (en) * 2005-05-25 2007-03-08 Guilford F T Liposomal formulation for oral administration of glutathione (reduced) and/or methylcobalamine for diseases related to glutathione deficiency and deficiency of the methionine remethylation pathway

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) * 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US4879370A (en) * 1983-12-02 1989-11-07 Cornell Research Foundation, Inc. Glutathione delivery system
US4767785A (en) * 1984-01-18 1988-08-30 Michael Georgieff Hypocaloric preparation and intravenous method for hypocaloric treatment of patients
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
DE3707127C2 (de) * 1987-03-05 1996-06-20 Zambon Spa Verwendung von Methionin zur Behandlung von Immun-Schwächeerkrankungen bei Virusinfektionen und/oder bei Tumorerkrankungen
DE3812008A1 (de) * 1987-04-10 1988-10-20 Pfrimmer Pharma Verwendung von l-(-)-thiazolidin-4-carbonsaeure als cysteinquelle bei gestoerter cysteinsynthese
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
DE3906671A1 (de) * 1989-03-02 1990-09-06 Wulf Prof Dr Droege Orales, magenvertraegliches n-acetylcysteinpraeparat hoher dosierung

Also Published As

Publication number Publication date
OA09503A (en) 1992-11-15
PT92949A (pt) 1990-07-31
KR910700045A (ko) 1991-03-13
MX173567B (es) 1994-03-16
IL93162A0 (en) 1990-11-05
IE900073L (en) 1990-07-26
GB2243296B (en) 1992-10-21
GB2243296A (en) 1991-10-30
CA2045180A1 (en) 1990-07-27
CH683499A5 (it) 1994-03-31
CA1339070C (en) 1997-07-29
JPH04504570A (ja) 1992-08-13
WO1990008540A1 (en) 1990-08-09
GR900100048A (el) 1991-06-07
IE62795B1 (en) 1995-03-08
MA21739A1 (fr) 1990-10-01
FR2643557B1 (fr) 1995-02-03
AU4969490A (en) 1990-08-24
ZA90245B (en) 1990-10-31
NL9020094A (nl) 1991-10-01
AU639686B2 (en) 1993-08-05
PT92949B (pt) 1995-12-29
US5607974A (en) 1997-03-04
IT9019141A1 (it) 1991-07-24
LU87977A1 (fr) 1992-03-11
DK139191D0 (da) 1991-07-25
DK139191A (da) 1991-07-25
IT9019141A0 (it) 1990-01-24
IL93162A (en) 1995-03-15
TNSN90009A1 (fr) 1991-03-05
BE1004168A3 (fr) 1992-10-06
CA1339256C (en) 1997-08-12
KR940002820B1 (ko) 1994-04-04
GB9112420D0 (en) 1991-07-31
SE9101815D0 (sv) 1991-06-13
DE4090165T (ja) 1991-11-21
FR2643557A1 (fr) 1990-08-31
IT1237999B (it) 1993-06-21

Similar Documents

Publication Publication Date Title
SE9101815D0 (sv) Behandling av sjukdom foerbunden med hiv-infektioner
ES2125233T3 (es) Tratamiento de las infecciones retrovirales humanas con 2',3'-didesoxiinosina.
DE69111077T2 (de) Chinazolinderivate um die antitumorwirkung zu verbessern.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ES2160597T3 (es) Tratamiento y profilaxis de enfermedades producidas por parasitos o bacterias.
OA07291A (fr) Gilet orthopédique de soutien et de contention dans le traitement des traumatisés et des opérés de l'épaule, de la ceinture scapulaire et du membre supérieur.
ES2130114T3 (es) 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infeccion por hiv.
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
DE60139466D1 (de) Behandlung von diabetes
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ATE182271T1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
ES2058343T3 (es) Piridinas disubstituidas.
MD990258A (en) Method of treatment of the acute viral hepatitis B
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
ES2123510T3 (es) Uso de la 2-fenil-1,2-benciisoselenazol-3(2h)-ona.
NO970573L (no) Ylidenforbindelser og deres fremstilling
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
ATE108335T1 (de) Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
TR200003084T2 (tr) Paroxetine askorbat
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
BE900089A (fr) Utilisation de mini-somatostatines en therapeutique.
ATE121935T1 (de) D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren.
HUP9900045A2 (hu) Javított, leukémiásvér-alapú készítmény és alkalmazása a gyógyászatban
IT7829846A0 (it) Composizione farmaceutica per la cura della sordita' e del ronzio auricolare.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9101815-0

Format of ref document f/p: F